ZARVY

Invokana 300mg is an original branded medication developed and manufactured by Johnson & Johnson Pvt Ltd. It contains Canagliflozin, a powerful SGLT2 inhibitor that effectively manages type 2 diabetes mellitus. By inhibiting the sodium-glucose cotransporter-2 (SGLT2) in the kidneys, Invokana increases glucose excretion through urine, thereby reducing blood sugar levels. This mechanism not only supports glycemic control but also provides significant cardiovascular and renal benefits. Additionally, Invokana 300mg helps reduce HbA1c, supports weight management, and lowers the risk of diabetic kidney complications. Available through trusted online pharmacy platforms, it is often compared with alternatives such as Glucophage, Forxiga, Jardiance, Ozempic, Wegovy, and Rebelsus, making it a comprehensive choice for diabetes management.

Cetapin 500mg contains Metformin 500mg, a well-established oral antidiabetic medication manufactured by Sanofi. It is primarily prescribed for the management of type 2 diabetes mellitus, helping to regulate blood sugar levels. Cetapin 500mg is also used off-label for conditions such as polycystic ovary syndrome (PCOS) and prediabetes to improve metabolic health. Metformin works by decreasing glucose production in the liver, improving insulin sensitivity, and enhancing glucose uptake by the muscles. This multi-faceted approach helps maintain optimal blood sugar levels, preventing complications associated with diabetes such as neuropathy, retinopathy, and cardiovascular issues.

Cetapin XR 1000mg contains Metformin 1000mg in an extended-release formulation, manufactured by Sanofi. It is widely used for the management of type 2 diabetes mellitus, helping patients achieve consistent blood sugar control throughout the day. The extended-release formulation ensures a gradual release of the medication, minimizing spikes in blood glucose levels and reducing the risk of gastrointestinal side effects often associated with immediate-release formulations. Cetapin XR 1000mg is also utilized off-label for managing prediabetes and polycystic ovary syndrome (PCOS). It works by reducing hepatic glucose production, improving insulin sensitivity, and enhancing peripheral glucose uptake, contributing to better overall glycemic control and metabolic health.

Metlong 500mg contains Metformin 500mg, manufactured by Panacea Biotec Ltd. It is a widely used oral antidiabetic medication, primarily indicated for the management of type 2 diabetes mellitus. Metlong 500mg helps regulate blood sugar levels, reducing the risk of complications such as neuropathy, retinopathy, and cardiovascular issues. Metformin works by decreasing glucose production in the liver, improving insulin sensitivity, and enhancing glucose uptake in peripheral tissues. Metlong 500mg is also effective in managing conditions like prediabetes and polycystic ovary syndrome (PCOS), promoting overall metabolic health and preventing the progression of diabetes.

Metlong DS 1000mg contains Metformin 1000mg, manufactured by Panacea Biotec Ltd. This dual-strength formulation is specifically designed to manage type 2 diabetes mellitus, providing effective blood sugar control throughout the day. Metlong DS 1000mg is particularly suited for patients who require higher doses of Metformin for glycemic regulation. Metformin works by decreasing glucose production in the liver, improving insulin sensitivity, and enhancing glucose uptake in peripheral tissues. It is also effective in managing prediabetes and polycystic ovary syndrome (PCOS), promoting metabolic balance and preventing the progression of diabetes-related complications.

Vokanamet 50/500mg is an original dual-action medication manufactured by Johnson & Johnson Pvt Ltd. It combines Canagliflozin (50mg), an SGLT2 inhibitor, with Metformin (500mg), a biguanide, to provide superior management of type 2 diabetes mellitus. Canagliflozin lowers blood sugar by reducing glucose reabsorption in the kidneys and increasing its excretion through urine. Metformin decreases hepatic glucose production, enhances insulin sensitivity, and improves glucose uptake in peripheral tissues. Together, they ensure effective glycemic control, while also providing cardiovascular and renal benefits for patients at risk of diabetic complications.

Vokanamet 50/1000mg is an original dual-action medication manufactured by Johnson & Johnson Pvt Ltd. It combines Canagliflozin (50mg), an SGLT2 inhibitor, with Metformin (1000mg), a biguanide, to deliver comprehensive management of type 2 diabetes mellitus. Canagliflozin reduces glucose reabsorption in the kidneys, increasing urinary glucose excretion, while Metformin decreases hepatic glucose production and improves insulin sensitivity. Together, they provide superior glycemic control and deliver additional cardiovascular and renal benefits, making this therapy particularly valuable for patients at risk of heart or kidney complications. Beyond blood sugar regulation, Vokanamet 50/1000mg also supports weight management and overall metabolic health, positioning it as an essential treatment option for lifestyle-related diseases.

Donamem 10 is a fixed-dose combination of donepezil 5mg and memantine 10mg, designed for the treatment of moderate to severe Alzheimer’s disease. This dual-action therapy integrates two evidence-based mechanisms to provide comprehensive management of cognitive decline and behavioral symptoms in neurodegenerative disorders. Donepezil enhances cholinergic transmission by inhibiting acetylcholinesterase, thereby sustaining acetylcholine levels necessary for memory and learning. In parallel, memantine acts as an NMDA receptor antagonist, mitigating glutamate-induced excitotoxicity, a key factor in neuronal death. This synergistic combination supports not only memory and orientation but also reduces aggression, confusion, and loss of function. Donamem 10 is especially helpful in patients who have already shown a stable response to separate dosing of memantine and donepezil, offering a simplified regimen that improves medication adherence and long-term therapeutic outcomes.

Admenta 5 is a generic formulation of memantine 5mg, a non-competitive NMDA receptor antagonist widely used in the treatment of moderate to severe Alzheimer's disease. By regulating the activity of glutamate—a neurotransmitter involved in learning and memory—Admenta 5 helps to protect neurons from excitotoxicity and supports cognitive stability in neurodegenerative conditions. Unlike acetylcholinesterase inhibitors, memantine acts through a different mechanism that is especially effective in the later stages of dementia, offering complementary benefits when used in combination therapy. Admenta 5 is clinically proven to delay cognitive decline, improve daily living activities, and reduce agitation and confusion in patients with advanced Alzheimer’s. It is also used in other forms of dementia, where it may help alleviate behavioral symptoms and enhance mental clarity, particularly in cases where disorientation, poor attention, and memory loss dominate.

Admenta 10 is a generic version of memantine 10mg, an NMDA receptor antagonist prescribed for patients with moderate to severe Alzheimer’s disease. It works by protecting nerve cells from damage caused by excessive levels of glutamate—a neurotransmitter involved in learning and memory. This protective mechanism helps slow cognitive decline and stabilize neurological function in individuals suffering from neurodegenerative conditions. As Alzheimer’s progresses into more advanced stages, glutamatergic overstimulation becomes more pronounced, and Admenta 10 provides targeted relief by reducing neuronal excitotoxicity. Unlike acetylcholinesterase inhibitors, which increase acetylcholine levels, memantine focuses on regulating glutamate activity, making it an effective component in combination therapy. Admenta 10 is also used in broader dementia cases, such as vascular or mixed-type dementia, where it can ease behavioral disturbances like confusion, aggression, or disorientation. Its long-term tolerability and non-addictive nature make it ideal for elderly populations needing extended cognitive support.

Donfox-M 5/10 is a fixed-dose combination of donepezil 5mg and memantine 10mg, formulated to provide enhanced management of moderate to severe Alzheimer’s disease. By uniting the cholinergic-boosting properties of donepezil with the neuroprotective action of memantine, this medication targets the two central mechanisms of cognitive decline: acetylcholine deficiency and glutamate-induced excitotoxicity. Donepezil increases acetylcholine levels by inhibiting the enzyme acetylcholinesterase, which is crucial for memory formation and cognitive clarity. Memantine, meanwhile, blocks overactive NMDA receptors to reduce glutamate-mediated neuron damage, improving brain resilience and long-term function. Donfox-M 5/10 helps improve memory, language skills, orientation, and behavior in patients whose cognitive symptoms have progressed beyond the early stage. It also reduces episodes of confusion, apathy, and restlessness, thereby improving the quality of life and independence of patients and easing caregiver burden.

Alzil-M Forte is a fixed-dose combination tablet that contains donepezil 10mg and memantine 10mg, specifically formulated for the management of moderate to severe Alzheimer's disease. This dual-ingredient approach integrates two pharmacological mechanisms—enhancing cholinergic function and mitigating excitotoxic neuronal damage—to provide comprehensive cognitive and behavioral support. Donepezil acts by inhibiting acetylcholinesterase, thereby maintaining acetylcholine levels essential for memory, attention, and learning. Memantine, an NMDA receptor antagonist, modulates excessive glutamate activity to prevent overstimulation and neurodegeneration. Together, they form a synergistic regimen that targets the complex pathology of Alzheimer’s. Alzil-M Forte offers significant improvements in mental clarity, daily functioning, and emotional stability. It is particularly effective in patients who have already responded well to individual therapy and require long-term, simplified dosing to maintain therapeutic continuity and compliance.

Jardiancemet 5/500mg is an original-branded medication with a combination therapy for managing Type 2 diabetes. Manufactured by Boehringer Ingelheim, it contains Empagliflozin 5mg (an SGLT-2 inhibitor) and Metformin 500mg (a first-line diabetes treatment). This dual-action formula effectively lowers blood sugar levels by reducing glucose absorption and increasing glucose excretion. It also provides weight management benefits and may support cardiovascular and liver health.

Jardiancemet 12.5/500mg is an original branded medication, manufactured by Boehringer Ingelheim. It is a combination therapy designed for Type 2 diabetes management, containing Empagliflozin 12.5mg (an SGLT-2 inhibitor) and Metformin 500mg (a first-line diabetes treatment). This dual-action medication effectively lowers blood sugar levels by reducing glucose production in the liver and increasing glucose excretion through urine. In addition to controlling diabetes, Jardiancemet supports weight management and may provide cardiovascular and liver health benefits.

Xigduo XR 10/500mg is an original branded medication developed by AstraZeneca for Type 2 diabetes management. It combines Dapagliflozin 10mg (an SGLT-2 inhibitor) and Metformin 500mg (a first-line diabetes treatment) in an extended-release (XR) formulation. This combination effectively controls blood sugar levels, supports weight management, and may offer cardiovascular and liver health benefits. The extended-release design allows for gradual absorption, reducing the risk of gastrointestinal discomfort associated with immediate-release Metformin.

Xigduo XR 10/1000mg is an original branded medication developed by AstraZeneca for the management of Type 2 diabetes. It combines Dapagliflozin 10mg, an SGLT-2 inhibitor, and Metformin 1000mg, a first-line diabetes treatment, in an extended-release (XR) formulation. This dual-action therapy lowers blood sugar levels by enhancing insulin sensitivity, reducing glucose production in the liver, and increasing glucose excretion through urine. The XR formulation ensures gradual absorption, minimizing gastrointestinal side effects commonly associated with Metformin.

Gibtulio Met 12.5/1000mg is a combination therapy for Type 2 diabetes management, developed by Lupin Ltd. It contains Empagliflozin 12.5mg (an SGLT-2 inhibitor) and Metformin 1000mg (a first-line diabetes treatment). This dual-action medication works by reducing glucose production in the liver and increasing glucose excretion through urine. In addition to blood sugar control, it supports weight management and may provide cardiovascular and liver health benefits.

Oxramet 5/1000mg is a combination therapy for Type 2 diabetes management, developed by Sun Pharmaceutical Industries Ltd. It contains Dapagliflozin 5mg (an SGLT-2 inhibitor) and Metformin 1000mg (a first-line diabetes treatment). This dual-action medication helps regulate blood sugar levels by reducing glucose production in the liver and increasing glucose excretion through urine. Additionally, it supports weight management and cardiovascular health while offering potential liver health benefits.